Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Molecular Tumor Board Helps in Advanced Cancer Cases

With accelerating development of personalized cancer treatments matched to a patient’s DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.

Editor’s note: Learn more about personalized medicine and molecular (genetic) testing on our website.


Molecular Tumor Board Helps in Advanced Cancer Cases

With accelerating development of personalized cancer treatments matched to a patient’s DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.

Editor’s note: Learn more about personalized medicine and molecular (genetic) testing on our website.


Molecular Tumor Board Helps in Advanced Cancer Cases

With accelerating development of personalized cancer treatments matched to a patient’s DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.

Editor’s note: Learn more about personalized medicine and molecular (genetic) testing on our website.


Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders

“Exceptional responders — those patients with cancer who demonstrate sustained benefit from a therapy on which almost all others fail — have been observed in clinical trials for decades.

“ ‘This is the basis of the urban legend story that everyone has heard — someone was given 2 months to live, but was given a drug and had a miraculous recovery,’ William C. Hahn, MD, PhD, chief of the division of molecular cellular oncology at Dana-Farber Cancer Institute, told HemOnc Today.

“Because of recent strides in genomic sequencing, however, the phenomenon has evolved from a series of unexplained individual success stories into a collection of tremendously valuable case studies.”


Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders

“Exceptional responders — those patients with cancer who demonstrate sustained benefit from a therapy on which almost all others fail — have been observed in clinical trials for decades.

“ ‘This is the basis of the urban legend story that everyone has heard — someone was given 2 months to live, but was given a drug and had a miraculous recovery,’ William C. Hahn, MD, PhD, chief of the division of molecular cellular oncology at Dana-Farber Cancer Institute, told HemOnc Today.

“Because of recent strides in genomic sequencing, however, the phenomenon has evolved from a series of unexplained individual success stories into a collection of tremendously valuable case studies.”


Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders

“Exceptional responders — those patients with cancer who demonstrate sustained benefit from a therapy on which almost all others fail — have been observed in clinical trials for decades.

“ ‘This is the basis of the urban legend story that everyone has heard — someone was given 2 months to live, but was given a drug and had a miraculous recovery,’ William C. Hahn, MD, PhD, chief of the division of molecular cellular oncology at Dana-Farber Cancer Institute, told HemOnc Today.

“Because of recent strides in genomic sequencing, however, the phenomenon has evolved from a series of unexplained individual success stories into a collection of tremendously valuable case studies.”